12.14
0.86 (7.62%)
| Penutupan Terdahulu | 11.28 |
| Buka | 11.50 |
| Jumlah Dagangan | 4,162,864 |
| Purata Dagangan (3B) | 2,388,979 |
| Modal Pasaran | 1,827,810,432 |
| Harga / Buku (P/B) | 14.11 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -9.25 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 13.68% |
| Nisbah Semasa (MRQ) | 2.33 |
| Aliran Tunai Operasi (OCF TTM) | -644.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -394.10 M |
| Pulangan Atas Aset (ROA TTM) | -129.99% |
| Pulangan Atas Ekuiti (ROE TTM) | -316.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Biohaven Ltd. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 2.13 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 11.96% |
| % Dimiliki oleh Institusi | 90.75% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Suvretta Capital Management, Llc | 31 Mar 2026 | 10,286,937 |
| Infinitum Asset Management, Llc | 31 Mar 2026 | 6,250,000 |
| Stempoint Capital Lp | 31 Mar 2026 | 3,188,982 |
| Knoll Capital Management, Llc | 31 Mar 2026 | 2,328,602 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |